Nutech Mediworld has developed a Human Embryonic Stem Cell (HESC) therapy that helps in treating type-II diabetes patients who are on conventional pills and insulin treatment.
Through the HESC therapy, insulin-producing cells are grown in human body without the need for a donor match.
Nutech Mediworld, the human embryonic stem cell transplant center based in Delhi, has developed disease-wise efficacy assessment parameters, and also established the quality and safety protocol to treat patients with human embryonic stem cell transplantation.
"We have developed HESC therapy and already received patents from 66 countries including the US, Australia, Japan, New Zealand and Israel," said Geeta Shroff, Medical Director, Nutech Mediworld Hospital.
The ready-to-use product has a shelf-life of six months, so that it can be made available to patients globally at their convenience.
The therapy will cost around Rs 1,80,000 for six weeks treatment and Nutech is looking for partners to tie up for expanding the treatment to other cities across the country, she added.
Type-II diabetes, which accounts for 90 percent of all diabetes cases, is a silent killer and much harder to treat than type I. It typically occurs in adults as a result of excess weight or hormonal imbalance.